Skip to main content

''As we continue to see increasing demand for RUCONEST® in the treatment of HAE, we are pleased to announce this step forward in this paediatric label expansion. This will enable us to treat attacks of patients of all ages living with HAE in the EU''

- Sijmen de Vries - CEO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline